Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer

Inclusion Criteria: * Radiologic confirmation of unresectable locally advanced pancreatic cancer by at least CT of chest and abdomen * Screening must be performed no longer than 2 weeks prior to study inclusion * Maximum tumor diameter ≤ 5 cm * Histological or cytological confirmation of pancreatic adenocarcinoma; * Age ≥ 18 years * PS-classification 0 - 2 * Life expectancy of at least 12 weeks * Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to definite inclusion; * Hemoglobin level ≥ 115 g/L * Platelet count ≥ 100\*109/l * Neutrophil count ≥ 2×109/L; * White blood cell count ≥ 4 ×109/L; * ALT and AST ≤ 2.5 x ULN * Serum creatinine ≤ 1.5 x ULN or a calculated creatinine clearance ≥ 50 ml/min * Prothrombin time or INR \< 1.5 x ULN * Written informed consent Exclusion Criteria: * Resectable pancreatic adenocarcinoma as discussed by our multidisciplinary hepatobiliary team * History of epilepsy * History of cardiac disease: * Cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers for antihypertensive regimen are permitted) * Compromised liver function (e.g. signs of portal hypertension, INR \> 1,5 without use of anticoagulants, ascites) * Uncontrolled infections (\> grade 2 NCI-CTC version 3.0) * Pregnant. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment * Allergy to contrast media * Any implanted stimulation device * Any implanted metal stent/device within the area of ablation that cannot be removed